Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9355 |
High Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.925 |
High Similarity |
NPD1610 |
Phase 2 |
0.9237 |
High Similarity |
NPD1548 |
Phase 1 |
0.9194 |
High Similarity |
NPD4908 |
Phase 1 |
0.8819 |
High Similarity |
NPD4625 |
Phase 3 |
0.8615 |
High Similarity |
NPD1613 |
Approved |
0.8615 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8516 |
High Similarity |
NPD2861 |
Phase 2 |
0.8492 |
Intermediate Similarity |
NPD4749 |
Approved |
0.8462 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.845 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8409 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.8409 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.8372 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8333 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.8321 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.8273 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.8273 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.8244 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8235 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8235 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.8175 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8085 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8085 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.8034 |
Intermediate Similarity |
NPD940 |
Approved |
0.8034 |
Intermediate Similarity |
NPD846 |
Approved |
0.8014 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7986 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7959 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7934 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7923 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7923 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.792 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7917 |
Intermediate Similarity |
NPD968 |
Approved |
0.7907 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7899 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7883 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7883 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7883 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7879 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7877 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7863 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7852 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7851 |
Intermediate Similarity |
NPD290 |
Approved |
0.7832 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7808 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7794 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7794 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7786 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.777 |
Intermediate Similarity |
NPD6099 |
Approved |
0.777 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.777 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7744 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.773 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.773 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7703 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7698 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7698 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7698 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7698 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7681 |
Intermediate Similarity |
NPD1607 |
Approved |
0.768 |
Intermediate Similarity |
NPD7843 |
Approved |
0.768 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7676 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7676 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7669 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7667 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7651 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7647 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7615 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7615 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7612 |
Intermediate Similarity |
NPD3691 |
Phase 2 |
0.7612 |
Intermediate Similarity |
NPD3690 |
Phase 2 |
0.7607 |
Intermediate Similarity |
NPD2860 |
Approved |
0.7607 |
Intermediate Similarity |
NPD2859 |
Approved |
0.7584 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7581 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7571 |
Intermediate Similarity |
NPD3846 |
Clinical (unspecified phase) |
0.7569 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7556 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7552 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.754 |
Intermediate Similarity |
NPD821 |
Approved |
0.7521 |
Intermediate Similarity |
NPD2933 |
Approved |
0.7521 |
Intermediate Similarity |
NPD2934 |
Approved |
0.75 |
Intermediate Similarity |
NPD7157 |
Approved |
0.75 |
Intermediate Similarity |
NPD2200 |
Suspended |
0.75 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD2557 |
Approved |
0.75 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7468 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7463 |
Intermediate Similarity |
NPD3225 |
Approved |
0.7463 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7462 |
Intermediate Similarity |
NPD6580 |
Approved |
0.7462 |
Intermediate Similarity |
NPD6581 |
Approved |
0.7448 |
Intermediate Similarity |
NPD6666 |
Approved |
0.7448 |
Intermediate Similarity |
NPD6667 |
Approved |
0.7442 |
Intermediate Similarity |
NPD3596 |
Phase 2 |
0.744 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7436 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7434 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7431 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7429 |
Intermediate Similarity |
NPD3052 |
Approved |
0.7429 |
Intermediate Similarity |
NPD3054 |
Approved |
0.7417 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7413 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7405 |
Intermediate Similarity |
NPD6830 |
Clinical (unspecified phase) |
0.7405 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7397 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7394 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7391 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7388 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7388 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7388 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7383 |
Intermediate Similarity |
NPD8158 |
Clinical (unspecified phase) |
0.7376 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7357 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7357 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7348 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7347 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7338 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7328 |
Intermediate Similarity |
NPD1894 |
Discontinued |
0.7325 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7325 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7325 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7324 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7315 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7313 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.731 |
Intermediate Similarity |
NPD4535 |
Phase 3 |
0.7305 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7303 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7296 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7286 |
Intermediate Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.7286 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7286 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7285 |
Intermediate Similarity |
NPD6072 |
Discontinued |
0.7279 |
Intermediate Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.7279 |
Intermediate Similarity |
NPD7041 |
Phase 2 |
0.7279 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7273 |
Intermediate Similarity |
NPD3049 |
Approved |
0.7273 |
Intermediate Similarity |
NPD3445 |
Approved |
0.7273 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7273 |
Intermediate Similarity |
NPD4476 |
Approved |
0.7273 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD3444 |
Approved |
0.7273 |
Intermediate Similarity |
NPD4477 |
Approved |
0.7273 |
Intermediate Similarity |
NPD3443 |
Approved |
0.7267 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7259 |
Intermediate Similarity |
NPD3685 |
Discontinued |
0.7254 |
Intermediate Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7246 |
Intermediate Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7239 |
Intermediate Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.7234 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7222 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7222 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7222 |
Intermediate Similarity |
NPD7030 |
Discontinued |
0.7222 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.7219 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7218 |
Intermediate Similarity |
NPD2556 |
Approved |
0.7218 |
Intermediate Similarity |
NPD5238 |
Clinical (unspecified phase) |
0.7218 |
Intermediate Similarity |
NPD2554 |
Approved |
0.7218 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7214 |
Intermediate Similarity |
NPD6405 |
Approved |
0.7214 |
Intermediate Similarity |
NPD6407 |
Approved |
0.7214 |
Intermediate Similarity |
NPD7477 |
Discontinued |
0.7209 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7209 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7208 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7206 |
Intermediate Similarity |
NPD7258 |
Clinical (unspecified phase) |
0.7197 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7192 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.719 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.719 |
Intermediate Similarity |
NPD7046 |
Clinical (unspecified phase) |
0.7188 |
Intermediate Similarity |
NPD228 |
Approved |
0.7185 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7185 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7185 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.7183 |
Intermediate Similarity |
NPD6353 |
Approved |
0.7181 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7179 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7176 |
Intermediate Similarity |
NPD7340 |
Approved |
0.7167 |
Intermediate Similarity |
NPD1809 |
Phase 2 |
0.7164 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7164 |
Intermediate Similarity |
NPD3847 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD3056 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD7294 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD845 |
Approved |
0.7143 |
Intermediate Similarity |
NPD1296 |
Phase 2 |
0.7132 |
Intermediate Similarity |
NPD6543 |
Approved |
0.7132 |
Intermediate Similarity |
NPD6539 |
Approved |
0.7132 |
Intermediate Similarity |
NPD6540 |
Phase 3 |
0.7132 |
Intermediate Similarity |
NPD6542 |
Approved |
0.7124 |
Intermediate Similarity |
NPD37 |
Approved |
0.7123 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7115
|
Intermediate Similarity |
NPD6234 |
Discontinued |